


بسم الله الرحمن الرحيم





شبكة المعلومات الجامعية التوثيق الالكتروني والميكرو فيلم



جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار






بعض الوثائق الأصلية تالفة





بالرسالة صفحات
لم ترد بالأصل





Role of Trans-Thoracic Echocardiography in Assessment of Cardiac Functions in Patients with Chronic Hepatitis C Treated with Directly Acting Antivirals

Thesis

*Submitted for Partial Fulfillment of
M.D. Degree in Cardiology*

By

Mohamed Gamal Mohamed Ibrahim

M.B.B.Ch, Master Degree in Cardiology, Ain Shams University

Under Supervision of

Prof. Dr. Ahmed Abd El Rahman Sharaf El Din

Professor of Cardiology

Faculty of Medicine, Ain Shams University

Dr. Nevine Ibrahim Mousa

Professor of Internal Medicine, Gastroenterology and Hepatology

Faculty of Medicine, Ain Shams University

Dr. Ahmed Mohamed Abo Bakr El Misiri

Assistant Professor of Cardiology

Faculty of Medicine, Ain Shams University

Dr. Tarek Khairy Mousa

Lecturer of Cardiology

Faculty of Medicine, Ain Shams University

Faculty of Medicine - Ain Shams University

2020

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

سُبْحَانَكَ لَا عِلْمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgments

*First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.*

*My deepest gratitude to my supervisor, **Prof. Dr. Ahmed Abd El Rahman Sharaf El Din**, Professor of Cardiology, Faculty of Medicine, Ain Shams University, for his valuable guidance and expert supervision, in addition to his great deal of support and encouragement. I really have the honor to complete this work under his supervision.*

*I would like to express my great and deep appreciation and thanks to **Dr. Mevane Ibrahim Mousa**, Professor of Internal Medicine, Gastroenterology and Hepatology, Faculty of Medicine, Ain Shams University, for his meticulous supervision, and his patience in reviewing and correcting this work.*

*I must express my deepest thanks to **Dr. Ahmed Mohamed Abo Bakr El Misiri**, Assistant Professor of Cardiology, Faculty of Medicine, Ain Shams University, for guiding me throughout this work and for granting me much of her time. I greatly appreciate her efforts.*

*I can't forget to thank with all appreciation **Dr. Tarek Khairy Mousa**, Lecturer of Cardiology, Faculty of Medicine, Ain Shams University, whom tirelessly and freely gave comments on various drafts of this piece of work regarding the ozone work.*

Special thanks to my Parents, my Wife and all my Family members for their continuous encouragement, enduring me and standing by me.

Mohamed Gamal Mohamed Ibrahim

List of Contents

Title	Page No.
List of Tables.....	5
List of Figures	7
List of Abbreviations.....	9
Introduction	- 1 -
Aim of the Work	14
Review of Literature	
▪ Hepatitis C Virus in Egypt	15
▪ HCV, Cirrhosis & DAAS Cardiovascular Effects	20
Patients and Methods.....	36
Results.....	57
Discussion	92
Study Limitations	102
Conclusion	103
Recommendations	104
Summary.....	105
References	107
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Outcome of therapy with different DAA regimens in Egypt in 2015–2016.....	19
Table (2):	The <i>Child- Pugh classification</i> of liver cirrhosis.....	36
Table (3):	Grading of LV diastolic function	47
Table (4):	Demographic characteristics of the Study Groups.....	57
Table (5):	Prevalence of different risk factors in the study groups:.....	58
Table (6):	PAUS and fibro scan characteristics.	59
Table (7):	Child score prevalence in cirrhotic group.	60
Table (8):	Treatment regimens and duration.....	60
Table (9):	ECG characteristic of the treated groups	61
Table (10):	ECG characteristic of the treated groups continued; corrected QT.....	62
Table (11):	Echocardiographic characteristic of the treated groups before treatment:	63
Table (12):	Echocardiographic characteristic of the treated groups after treatment:	65
Table (13):	Diastolic function in the treatment groups before treatment:	67
Table (14):	Diastolic function in the treatment groups after treatment.	69
Table (15):	Diastolic filling grades.....	70
Table (16):	RV function assessment pretreatment.	71
Table (17):	RV function assessment post treatment.....	72
Table (18):	RVSP & MPAP pretreatment.....	73
Table (19):	RVSP & MPAP post-treatment.....	74
Table (20):	LV GLS & RV GLS before treatment	75
Table (21):	LV GLS & RV GLS after treatment.....	76
Table (22):	Effects of treatment on QT interval.....	77
Table (23):	Effects of treatment on systolic function in non-cirrhotic patients.	78

List of Tables (cont...)

Table No.	Title	Page No.
Table (24):	Effects of treatment on systolic function in cirrhotic patients.....	80
Table (25):	Effects of treatment on diastolic function in non-cirrhotic group.	82
Table (26):	Effects of treatment on diastolic function in cirrhotic group.	84
Table (27):	Effects of treatment on RV systolic function, RVSP and MPAP in non-cirrhotic group.....	86
Table (28):	Effects of treatment on RV systolic function, RVSP and MPAP in cirrhotic group.....	88
Table (29):	Effects of treatment on LV GLS & RV GLS in non-cirrhotic patients.....	90
Table (30):	Effects of treatment on LV GLS & RV GLS in cirrhotic patients.	91

List of Figures

Fig. No.	Title	Page No.
Figure (1):	HCV sero-prevalence in Egypt in (A) 2008 and (B) 2015	15
Figure (2):	Real-life SVR results with different DAA treatment regimens in the Egyptian national program	19
Figure (3):	Spectrum of the cardiovascular manifestations of HCV infection before and after sustained virological response (SVR)	20
Figure (4):	Cardiovascular alterations with HCV infection.....	21
Figure (5):	Algorithm for the diagnosis of cirrhotic cardiomyopathy.....	30
Figure (6):	LV assessment (a): M-mode assessment of LV dimensions in parasternal long axis view (b) LV volumes and EF measurement in apical four chamber view	44
Figure (7):	(a): Illustration of LA Diameter measurement by M-Mode at PLAX, (b): LA volume measurement in apical four chamber view	45
Figure (8):	Assessment of diastolic function using PWD across the mitral valve (a) and TDI along the mitral valve lateral annulus (b).....	46
Figure (9):	Tricuspid annular plane systolic excursion (TAPSE).....	48
Figure (10):	RV Fractional area change (FAC).....	49
Figure (11):	Maximum TR jet velocity estimating RVSP	50
Figure (12):	Illustrations of the Steps involved in speckle tracking echocardiography	53

List of Figures (cont...)

Fig. No.	Title	Page No.
Figure (13):	Segmental & global RV free wall strain,from case number (91)	55
Figure (14):	Echocardiographic characteristic of the treated groups before treatment.	64
Figure (15):	Echocardiographic characteristic of the treated groups after treatment:	66
Figure (16):	Diastolic function in treatment groups before treatment.	68
Figure (17):	Diastolic function in treatment groups after treatment.	69
Figure (18):	Effects of treatment on QT interval.....	77
Figure (19):	Effects of treatment on systolic function in non-cirrhotic patients.....	79
Figure (20):	Effects of treatment on systolic function in cirrhotic patients.	81
Figure (21):	Effects of treatment on diastolic function in non-cirrhotic group.	83
Figure (22):	Effects of treatment on diastolic function in cirrhotic group.	85
Figure (23):	Effects of treatment on RV systolic function, RVSP and MPAP in non-cirrhotic group.....	87
Figure (24):	Effects of treatment on RV systolic function, RVSP and MPAP in cirrhotic group.....	89

List of Abbreviations

Abb.	Full term
<i>BNP</i>	<i>Brain natriuretic peptide</i>
<i>Ca</i>	<i>Calcium</i>
<i>CCL2</i>	<i>Chemokine ligand 2</i>
<i>CCM</i>	<i>Cirrhotic cardiomyopathy</i>
<i>CKD</i>	<i>Chronic Kidney disease</i>
<i>CO</i>	<i>Carbon monoxide</i>
<i>DCV</i>	<i>Daclatasvir</i>
<i>DHS</i>	<i>Demographic Health Survey</i>
<i>DM</i>	<i>Diabetes mellitus</i>
<i>DT</i>	<i>Deceleration time</i>
<i>EASL</i>	<i>European Association for the Study of the Liver</i>
<i>ECG</i>	<i>Electrocardiography</i>
<i>EF</i>	<i>Ejection fraction</i>
<i>eGFR</i>	<i>Estimated glomerular filtration rate</i>
<i>FAC</i>	<i>Fractional area change</i> :
<i>FDA</i>	<i>Food and Drug Administration</i>
<i>GDP</i>	<i>Gross Domestic Product</i>
<i>GLS</i>	<i>Global longitudinal strain</i>
<i>HCC</i>	<i>Hepatocellular carcinoma</i>
<i>HCV</i>	<i>Hepatitis C virus</i>
<i>HIV</i>	<i>Human immunodeficiency viruses</i>
<i>HR</i>	<i>Heart rate</i>
<i>HTN</i>	<i>Hypertension</i>
<i>IL</i>	<i>Interleukin</i>
<i>IVC</i>	<i>Inferior vena cava</i>
<i>IVRT</i>	<i>Isovolumic relaxation time</i>
<i>K</i>	<i>Potassium</i>
<i>LA</i>	<i>Left atrium</i>
<i>LAVI</i>	<i>Left atrium volume index</i>
<i>LV GLS</i>	<i>Left ventricle global longitudinal strain</i>
<i>LV</i>	<i>Left Ventricle</i>
<i>LVEDD</i>	<i>Left ventricle end diastolic diameter</i>

List of Abbreviations (cont...)

Abb.	Full term
LVEDVI.....	<i>Left ventricle end diastolic volume index</i>
Mg.....	<i>Magnesium</i>
MPAP	<i>Mean pulmonary artery pressure</i>
NCCVH.....	<i>National Committee for Control of Viral Hepatitis</i>
NO	<i>Nitric Oxide</i>
PAD	<i>Peripheral arterial disease</i>
PEG	<i>Pegylated interferon</i>
RA.....	<i>right atrium</i>
RBV	<i>Ribavirin</i>
RNA	<i>Ribonucleic acid</i>
ROI	<i>Region of interest</i>
RV GLS	<i>Right ventricle global longitudinal strain</i>
RV.....	<i>Right ventricle</i>
RVSP	<i>Right ventricular systolic pressure</i>
SOF.....	<i>Sofosbuvir</i>
SPSS.....	<i>Statistical package for social science</i>
SVRs.....	<i>Sustained virological responses</i>
TAPSE.....	<i>Tricuspid annular plane systolic excursion</i>
TDI	<i>Doppler imaging</i>
TNF	<i>Tumor necrosis factor</i>
TR.....	<i>Tricuspid regurgitation</i>
WHO	<i>World Health Organization</i>